Side Effects of voclosporin: A Synthesis of Findings from 7 Studies

  1. Home
  2. Side Effects of voclosporin
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of voclosporin: A Synthesis of Findings from 7 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of voclosporin: A Synthesis of Findings from 7 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Voclosporin is a novel calcineurin inhibitor that was developed to prevent organ graft rejection and treat autoimmune diseases. 3 . It has shown efficacy in animal models of experimental autoimmune uveitis and in clinical trials for the prevention of renal allograft rejection and for plaque psoriasis. 4 . Voclosporin is similar in structure to cyclosporine A, but with a difference in one amino acid, resulting in superior calcineurin inhibition and less variability in plasma concentration. 3 . In clinical trials for non-infectious uveitis, voclosporin has demonstrated efficacy and tolerability. 4 , 3 .

Reasons for side effects

Voclosporin is an immunosuppressant, so it can increase the risk of infection. It also has calcineurin-inhibiting properties, which can cause kidney or liver dysfunction.

Common side effects

Infection

Voclosporin is an immunosuppressant, so it can increase the risk of infection. 4 , 3 .

Kidney dysfunction

Voclosporin can cause kidney dysfunction. 4 , 3 .

Liver dysfunction

Voclosporin can cause liver dysfunction. 4 , 3 .

Hypertension

Voclosporin can cause hypertension. 4 , 3 .

Tremor

Voclosporin can cause tremor. 4 , 3 .

Headache

Voclosporin can cause headache. 4 , 3 .

Gastrointestinal symptoms

Voclosporin can cause gastrointestinal symptoms (nausea, vomiting, diarrhea, etc.). 4 , 3 .

Side effect management

Infection

Voclosporin is an immunosuppressant, so it can increase the risk of infection. 4 , 3 . To prevent infection, it is important to maintain good hygiene practices, such as hand washing and gargling. It is also important to have regular health checks to detect infections early.

Kidney dysfunction

Voclosporin can cause kidney dysfunction. 4 , 3 . To prevent kidney dysfunction, it is important to have regular blood tests to monitor kidney function. It is also important to drink plenty of fluids.

Liver dysfunction

Voclosporin can cause liver dysfunction. 4 , 3 . To prevent liver dysfunction, it is important to have regular blood tests to monitor liver function. It is also important to avoid alcohol consumption.

Hypertension

Voclosporin can cause hypertension. 4 , 3 . To prevent hypertension, it is important to measure blood pressure regularly and take antihypertensive medications if necessary. It is also important to reduce salt intake.

Tremor

Voclosporin can cause tremor. 4 , 3 . If you are concerned about tremor, consult your doctor.

Headache

Voclosporin can cause headache. 4 , 3 . If you are concerned about headache, consult your doctor.

Gastrointestinal symptoms

Voclosporin can cause gastrointestinal symptoms (nausea, vomiting, diarrhea, etc.). 4 , 3 . If you are concerned about gastrointestinal symptoms, consult your doctor.

Comparison between studies

Commonalities

Multiple studies have confirmed the efficacy of voclosporin in treating non-infectious uveitis. 4 , 3 . It is also common knowledge that voclosporin is similar in structure to cyclosporine A, but with a difference in one amino acid, resulting in superior calcineurin inhibition and less variability in plasma concentration. 3 .

Differences

There are differences in the efficacy and incidence of side effects of voclosporin between studies. This is thought to be due to differences in study methods and patient characteristics.

Precautions for application in real life

Voclosporin is an immunosuppressant, so it can increase the risk of infection. 4 , 3 . Therefore, people taking voclosporin should maintain good hygiene practices, such as hand washing and gargling, and have regular health checks. If you feel unwell while taking voclosporin, consult your doctor immediately.

Limitations of current research

The long-term safety and efficacy of voclosporin have not yet been fully investigated. Therefore, further research is needed on the long-term side effects of voclosporin and comparisons with other treatments.

Future research directions

Research is needed to evaluate the long-term safety and efficacy of voclosporin. Research is also needed to optimize the dosage and duration of voclosporin administration. In addition, research is needed to evaluate the efficacy of combined treatments using voclosporin and other therapies.

Conclusion

Voclosporin is an effective drug for treating non-infectious uveitis. 4 , 3 . However, since voclosporin is an immunosuppressant, it can increase the risk of infection. 4 , 3 . It is important to follow your doctor's instructions carefully and have regular health checks when taking voclosporin.

Literature analysis of 7 papers
Positive Content
7
Neutral Content
0
Negative Content
0
Article Type
0
2
2
4
7
1.

Vigabatrin for refractory partial epilepsy.

Author: HemmingKarla, MaguireMelissa J, HuttonJane L, MarsonAnthony G

Epilepsy treatment
Visual field constriction

Vigabatrin, an antiepileptic drug for refractory epilepsy, is generally well-tolerated. However, long-term use has been associated with asymptomatic visual field constriction, highlighting the need for monitoring during treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

2.

Vigabatrin for refractory partial epilepsy.

Author: HemmingKarla, MaguireMelissa J, HuttonJane L, MarsonAnthony G

Refractory epilepsy treatment
Visual field constriction

Vigabatrin is an antiepileptic drug that is used for the treatment of refractory epilepsy. Although vigabatrin is generally well tolerated, it can cause asymptomatic visual field constriction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

6.

Emerging therapies for noninfectious uveitis: what may be coming to the clinics.

Author: MayaJose R, SadiqMohammad A, ZapataLiz J, HanoutMostafa, SarwarSalman, RajagopalanNithya, GuinnKathleen E, SepahYasir J, NguyenQuan Dong

Abatacept for NIU
EGP-437 for NIU
ESBA 105 for NIU
Gevokizumab for NIU
Sarilumab for NIU
Secukinumab for NIU
Sirolimus for NIU
Tocilizumab for NIU
Voclosporin for NIU

This review discusses emerging therapeutic agents and drug delivery systems for noninfectious uveitis (NIU), focusing on agents targeting specific pathways involved in inflammation. These include monoclonal antibodies against interleukins, antibody fragments against inflammatory cytokines, and T-cell inhibitors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies.

Author: Dall'EraM, SolomonsN, FedericoR, TrumanM

Improved safety
Reduced side effects
Lymphoproliferative disorders
Skin cancers

This retrospective propensity analysis suggests that a lower-dose regimen of mycophenolate mofetil and steroids may be equally effective and safer than the high-dose regimen for lupus nephritis. An ongoing randomized controlled trial is investigating the efficacy and safety of this lower-dose regimen.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.